Neeman & Industry News
DCGI to implement e-Gov in its working The Drugs Controller General of India (DCGI) to have a single window facility for drug approval soon...
New Indian Regulatory Guidance by Central Drugs Standard Control Organization Guidance for Industry on Submission of Clinical Trial Application for Evaluating Safety and Efficacy - Central Drugs Standard Control Organization...
Indian Clinical Data Management market is expected to ramp up to $150 million MNCs are more than willing to outsource their needs to India because of it\'s technological innovation, creditable quality, operational flexibility, cost effectiveness, time-to-market and competitive advantage according to Koteshwar Govind, Deputy Manager,...
India: Attractive Market for Biopharmaceutical Companies Looking to Accelerate Their Clinical Trials The Clinical Research Market in India is growing at a very rapid rate according to anyone’s statistics…It is exploding according to all the hype. ...

Neeman News

 
Clinical Trials for Multiple Sclerosis

Max Neeman is part of the global study enrolling patients with Relapsing-Remitting Multiple Sclerosis. This multi-center study spans across thirty countries which includes India. The study aims to enroll a total of 120 patients in India.

For more details on the study, please visit:

http://www.clinicaltrial.gov/ct2/show/NCT00451451?term=109MS302&rank=1&show_locs=Y#locn